Respiratory Virus Infection Drugs Market Size, Share & Report Forecast 2028

The global Respiratory Virus Infection Drugs market accrued earnings worth approximately 40.12 (USD Billion) in 2020 and is predicted to gain revenue of about 57.23(USD Billion) by 2028, is set to record a CAGR of nearly 7.5% over the period from 2021 to 2028. The report offers an assessment and analysis of the Respiratory Virus Infection Drugs market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, revenue estimates, opportunities, evolving trends, and industry-validated data. The report provides historical data from 2018 to 2020 along with a forecast from 2021 to 2028 based on revenue (USD Billion).

Request Free Sample

Respiratory Virus Infection Drugs Market: Overview

Respiratory viruses such as influenza, coronavirus, Para influenza, rhinovirus, respiratory syncytial virus, and human metapneumovirus are the most common causes of respiratory virus infections in immuno-compromised persons. Moreover, early diagnosis & treatment of these infections through drugs can prove to be effective & beneficial for immuno-compromised patients affected due to respiratory virus infections since viral replication & invasive infection can prove to be fatal. In the past few years newly emerging viral respiratory pathogens such as avian influenza, pandemic influenza, SARS-CoV, and MERS-CoV have been constantly posing challenges to private as well as public healthcare systems.

Hence, there is a growing necessity for developing cost-efficient anti-viral agents & drugs. Recently, antiviral drugs are being developed by virologists & pharmaceutical firms for targeting viral entry, virus replication, and virus release for inhibiting proliferation & blocking the growth & spread of viruses in the human body.

According to NIH researchers, Amantadine and Rimantadine medicines/pharmacokinetics are used for inhibiting replication of the influenza A virus by interfering with viral M2 protein activity. Moreover, both Amantadine and Rimantadine have proved to be effective in low proportions against influenza B virus. Reportedly, both these drugs are administered in oral form as tablets or in syrup form at 5mg per kg of body mass for children.

They are administered nearly up to 200 mg per day for adults. As per clinical trials, both Amantadine and Rimantadine have proved effective in preventing influenza in over 60% of subjects. For the record Zanamivir and Oseltamivir available for oral administration in powdered, capsule, and liquid form have also helped in preventing influenza infections in over 65% of subjects.

Respiratory Virus Infection Drugs Market: Growth Drivers

The massive use of artificial intelligence and machine learning in drug discovery is projected to favorably influence the growth of the respiratory virus infection drugs market. Humungous use of combination therapy is projected to boost the rate of success of treating respiratory virus infection through anti-viral drugs. This, in turn, will facilitate the elevation of the respiratory virus infection drug market size in upcoming years. Apart from this, effective drug delivery through nanotechnology is projected to provide new growth prospects for the respiratory virus infection drugs market in near future. In addition to this, a rise in healthcare spending & surge in vaccination activities will spur the respiratory virus infection drugs industry growth.

With an AI-based multi-program model enabling the production of antibiotic resistance drug molecules for various kinds of harmful viruses, the market for respiratory virus infection drugs is anticipated to gain traction in the years ahead. Giant pharma firms are trying to enter into partnerships with other local or regional pharma firms for developing new drugs for treating respiratory virus infections in children, thereby helping the respiratory virus infection drugs market explore new areas of growth in the ensuing years. Nonetheless, easy access to generic drug substitutes can pose a threat to the growth of the respiratory virus infection drugs market in near future.

Regional Landscape

North American Market To Hit New Terrains of Growth By 2028

The expansion of the respiratory virus infection drugs market during 2021-2028 can be attributed to new drug approvals by regulatory authorities such as U.S. FDA. Apart from this, the presence of enhanced healthcare amenities along with early acceptance of advanced therapeutics in the healthcare sector in countries like Canada and the U.S. will help the respiratory virus infection drugs market in North America gain acceleration. Apart from this, growing healthcare awareness among the people and easy access to diagnostic tests in the sub-continent will further contribute towards the growth of the respiratory virus infection drugs market in North America during 2021-2028.

Competitive Landscape

Key players leveraging the industry landscape and profiled in the report include AstraZeneca, AbbVie, GlaxoSmithKline plc, CHIESI Farmaceutici S.p.A., Roche Diagnostics Limited, Orion Corporation, Cipla, Inc., Sanofi, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, and Merck & Co., Inc.

Respiratory Virus Infection Drugs Market: Report Scope

The global Respiratory Virus Infection Drugs Market is segmented as follows:

By Drug Type

• Antibiotics
• Nasal Decongestants
• Non-Steroidal Anti-Inflammatory Drugs
• Cough Suppressants

By Infection Type

• Respiratory Syncytial Virus Infection 
• Influenza Virus Infection
• Para influenza Virus Infection
• Rhinovirus Infection
• Adenovirus Infection

By Distribution Channel

• Hospital Pharmacies
• Drug Stores
• Retail Pharmacies
• Clinics 

By Route of Administration

• Oral
• Parenteral

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa